MAPT and Alzheimer disease: Recently, the use of iPSC-derived cerebral organoids led to replicate in vitro some molecular determinants of Alzheimer’s disease, such as the Aβ and tau pathology and the subsequent synapses dysfunction (Gonzalez et al., 2018).